6541 — Tanvex Biopharma Cashflow Statement

0.000.00%

Last trade - 00:00

HealthcareSpeculativeSmall CapSucker Stock

Annual cashflow statement for Tanvex Biopharma, fiscal year end - December 31st, TWD millions except per share, conversion factor applied.

	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st	2025 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Net Income/Starting Line	-1,543	-1,641	-2,137	-1,381	-1,503
Depreciation
Amortisation
Non-Cash Items	6.35	120	367	39.5	120
Unusual Items
Other Non-Cash Items
Changes in Working Capital	-93.8	-94.2	10.8	-97.9	11.1
Change in Accounts Receivable
Change in Inventories
Change in Prepaid Expenses
Change in Accounts Payable
Change in Accrued Expenses
Change in Other Liabilities
Other Operating Cash Flow
Cash from Operating Activities	-1,387	-1,334	-1,434	-1,151	-1,005
Capital Expenditures	-30.3	-96.1	-71.3	-111	-670
Purchase of Fixed Assets
Purchase / Acquisition of Intangibles
Other Investing Cash Flow Items	5.66	-1.27	-12.2	1.51	972
Sale of Business
Sale of Fixed Assets
Sale/Maturity of Investment
Purchase of Investments
Other Investing Cash Flow
Cash from Investing Activities	-24.7	-97.4	-83.6	-109	302
Financing Cash Flow Items	—	—	—	—	0.222
Other Financing Cash Flow
Net Issuance / Retirement of Stock
Net Issuance / Retirement of Debt
Cash from Financing Activities	1,597	-123	1,080	1,255	1,138
Foreign Exchange Effects
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash	154	-1,437	-405	-3.79	502